Table 2.
Statistical comparison of clinical features among molecular subtypes.
| Subtype I | Subtype II | Subtype III | Subtype IV | Subtype V | Subtype VI | Fisher's exact test | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N = 37 | N = 34 | N = 41 | N = 81 | N = 41 | N = 93 | p value | |||||||
| Age at diagnosis | |||||||||||||
| < 50 yr | 27 | 73.0% | 16 | 47.1% | 30 | 73.2% | 54 | 66.7% | 22 | 53.7% | 54 | 58.1% | |
| >= 50 yr | 10 | 27.0% | 18 | 52.9% | 11 | 26.8% | 27 | 33.3% | 19 | 46.3% | 39 | 41.9% | 0.08 |
| T stage | |||||||||||||
| 1 | 8 | 21.6% | 4 | 11.8% | 10 | 24.4% | 16 | 19.8% | 22 | 53.7% | 41 | 44.1% | |
| 2 | 28 | 75.7% | 23 | 67.6% | 20 | 48.8% | 56 | 69.1% | 17 | 41.5% | 44 | 47.3% | |
| 3 | 1 | 2.7% | 5 | 14.7% | 7 | 17.1% | 5 | 6.2% | 1 | 2.4% | 7 | 7.5% | |
| 4 | 0 | 0.0% | 2 | 5.9% | 4 | 9.8% | 4 | 4.9% | 1 | 2.4% | 1 | 1.1% | 2.00E-05 |
| N stage | |||||||||||||
| 0 | 20 | 54.1% | 7 | 20.6% | 16 | 39.0% | 31 | 38.3% | 20 | 48.8% | 43 | 46.2% | |
| 1 | 10 | 27.0% | 10 | 29.4% | 8 | 19.5% | 25 | 30.9% | 12 | 29.3% | 22 | 23.7% | |
| 2 | 4 | 10.8% | 11 | 32.4% | 11 | 26.8% | 14 | 17.3% | 7 | 17.1% | 16 | 17.2% | |
| 3 | 3 | 8.1% | 6 | 17.6% | 6 | 14.6% | 11 | 13.6% | 2 | 4.9% | 12 | 12.9% | 0.26 |
| Pos. Lym. Nodes | |||||||||||||
| 0 | 20 | 54.1% | 6 | 17.6% | 16 | 39.0% | 31 | 38.3% | 20 | 48.8% | 43 | 46.2% | |
| 1-3 | 10 | 27.0% | 10 | 29.4% | 8 | 19.5% | 26 | 32.1% | 12 | 29.3% | 22 | 23.7% | |
| 4-9 | 4 | 10.8% | 11 | 32.4% | 10 | 24.4% | 13 | 16.0% | 7 | 17.1% | 16 | 17.2% | |
| > = 10 | 3 | 8.1% | 5 | 14.7% | 6 | 14.6% | 9 | 11.1% | 2 | 4.9% | 12 | 12.9% | 0.30 |
| M stage | |||||||||||||
| 0 | 36 | 97.3% | 33 | 97.1% | 40 | 97.6% | 78 | 96.3% | 41 | 100.0% | 91 | 97.8% | |
| 1 | 1 | 2.7% | 1 | 2.9% | 1 | 2.4% | 3 | 3.7% | 0 | 0.0% | 2 | 2.2% | 0.94 |
| TNM Stage | |||||||||||||
| I | 6 | 16.2% | 2 | 5.9% | 10 | 24.4% | 9 | 11.1% | 12 | 29.3% | 28 | 30.1% | |
| II | 23 | 62.2% | 13 | 38.2% | 11 | 26.8% | 46 | 56.8% | 18 | 43.9% | 36 | 38.7% | |
| II | 6 | 16.2% | 18 | 52.9% | 19 | 46.3% | 23 | 28.4% | 10 | 24.4% | 27 | 29.0% | |
| IV | 1 | 2.7% | 1 | 2.9% | 1 | 2.4% | 3 | 3.7% | 0 | 0.0% | 2 | 2.2% | 7.60E-04 |
| Nuclear Grade | |||||||||||||
| 1 | 1 | 2.7% | 0 | 0.0% | 2 | 4.9% | 2 | 2.5% | 9 | 22.0% | 17 | 18.3% | |
| 2 | 3 | 8.1% | 1 | 2.9% | 4 | 9.8% | 11 | 13.6% | 18 | 43.9% | 38 | 40.9% | |
| 3 | 30 | 81.1% | 28 | 82.4% | 33 | 80.5% | 62 | 76.5% | 10 | 24.4% | 33 | 35.5% | 0 |
| ER* | |||||||||||||
| positive | 0 (2) | 0.0% (5%) | 1 (6) | 2.9% (20.6%) | 10 (13) | 24.4% (36%) | 70 (66) | 86.4% (90.4%) | 41 (36) | 100.0% (97.2%) | 82 (75) | 88.2% (91.5%) | |
| negative | 37 (34)) | 100.0% (95%) | 33 (23) | 97.1% (79.4%) | 31 (23) | 75.6% (64%) | 11 (7) | 13.6% (9.6%) | 0 (1) | 0.0% (2.8%) | 11 (7) | 11.8% (8.5%) | 6.31E-51 |
| HER2* | |||||||||||||
| positive | 4 (2) | 10.8% (11.8%) | 26 (9) | 76.5% (81.8%) | 18 (16) | 43.9% (66.7%) | 22 (11) | 27.2% (33.3%) | 0 (2) | 0.0% (13.3%) | 5 (7) | 5.4% (15.9%) | |
| negative | 33 (17) | 89.2% (88.2%) | 8 (2) | 23.5% (18.2%) | 23 (8) | 56.1% (33.3%) | 59 (22) | 72.8% (66.7%) | 41 (13) | 100.0% (86.7%) | 88 (37) | 94.6% (84.1%) | 9.09E-20 |
| PR* | |||||||||||||
| positive | 19 (9) | 51.4% (25%) | 14 (11) | 41.2% (37.9%) | 23 (16) | 56.1% (44.4%) | 73 (64) | 90.1% (87.7%) | 41 (34) | 100.0% (91.9%) | 88 (70) | 94.6% (85.4%) | |
| negative | 18 (27) | 48.6% (75%) | 20 (18) | 58.8% (62.1%) | 18 (20) | 43.9% (55.6%) | 8 (9) | 9.9% (12.3%) | 0 (3) | 0.0% (8.1%) | 5 (12) | 5.4% (14.6%) | 2.26E-18 |
| Local Relapse | |||||||||||||
| No | 31 | 83.8% | 27 | 79.4% | 39 | 95.1% | 68 | 84.0% | 34 | 82.9% | 86 | 92.5% | |
| Yes | 6 | 16.2% | 4 | 11.8% | 1 | 2.4% | 8 | 9.9% | 3 | 7.3% | 6 | 6.5% | 0.29 |
| Regional Relapse | |||||||||||||
| No | 32 | 86.5% | 26 | 76.5% | 37 | 90.2% | 67 | 82.7% | 36 | 87.8% | 84 | 90.3% | |
| Yes | 2 | 5.4% | 5 | 14.7% | 3 | 7.3% | 6 | 7.4% | 1 | 2.4% | 8 | 8.6% | 0.54 |
| Distant metastasis | |||||||||||||
| No | 31 | 83.8% | 15 | 44.1% | 33 | 80.5% | 50 | 61.7% | 39 | 95.1% | 70 | 75.3% | |
| Yes | 6 | 16.2% | 16 | 47.1% | 8 | 19.5% | 29 | 35.8% | 2 | 4.9% | 22 | 23.7% | 2.51E-05 |
*: Numbers in parentheses are results determined by immunohistochemistry. For HER2, 3+ was regarded as positive. P values for ER, HER2 and PR by IHC among all six molecular subtypes were 3 × 10-36, 2 × 10-4 and 1.4 × 10-14, respectively.